Fighting Poor-Quality Medicines in Low- And Middle-Income Countries: The Importance of Advocacy and Pedagogy

Hdl Handle:
http://hdl.handle.net/10144/618719
Title:
Fighting Poor-Quality Medicines in Low- And Middle-Income Countries: The Importance of Advocacy and Pedagogy
Authors:
Ravinetto, R; Vandenbergh, D; Macé, C; Pouget, C; Renchon, B; Rigal, J; Schiavetti, B; Caudron, JM
Journal:
Journal of Pharmaceutical Policy and Practice
Abstract:
The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups, who were in a privileged position to witness the gap in quality of medicines between high-income countries and low- and middle-income countries. Despite an increasing awareness of the problem and the launch of some positive initiatives, the divide in pharmaceutical quality between the North and the South remains important, and insufficiently addressed. More advocacy is needed for universal access to quality-assured medicines. It should target all those who are strongly "involved" with medicines: regulators, international organizations, journalists, purchasers, prescribers, program managers, policy makers, public health actors and the patients. Advocacy should be based on evidence from research and monitoring programs, and technical concepts should be translated in lay language through communication tools that address all the stakeholders. The fight to ensure universal access to quality medicines needs the participation of all, and can only be successful if grounded in common understanding.
Publisher:
BioMed Central
Issue Date:
10-Nov-2016
URI:
http://hdl.handle.net/10144/618719
DOI:
10.1186/s40545-016-0088-0
PubMed ID:
27843547
Submitted date:
2016-11-28
Language:
en
Appears in Collections:
Health Politics

Full metadata record

DC FieldValue Language
dc.contributor.authorRavinetto, Ren
dc.contributor.authorVandenbergh, Den
dc.contributor.authorMacé, Cen
dc.contributor.authorPouget, Cen
dc.contributor.authorRenchon, Ben
dc.contributor.authorRigal, Jen
dc.contributor.authorSchiavetti, Ben
dc.contributor.authorCaudron, JMen
dc.date.accessioned2016-11-29T15:59:44Z-
dc.date.available2016-11-29T15:59:44Z-
dc.date.issued2016-11-10-
dc.date.submitted2016-11-28-
dc.identifier.citationFighting Poor-Quality Medicines in Low- And Middle-Income Countries: The Importance of Advocacy and Pedagogy. 2016, 9:36 J Pharm Policy Practen
dc.identifier.pmid27843547-
dc.identifier.doi10.1186/s40545-016-0088-0-
dc.identifier.urihttp://hdl.handle.net/10144/618719-
dc.description.abstractThe globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups, who were in a privileged position to witness the gap in quality of medicines between high-income countries and low- and middle-income countries. Despite an increasing awareness of the problem and the launch of some positive initiatives, the divide in pharmaceutical quality between the North and the South remains important, and insufficiently addressed. More advocacy is needed for universal access to quality-assured medicines. It should target all those who are strongly "involved" with medicines: regulators, international organizations, journalists, purchasers, prescribers, program managers, policy makers, public health actors and the patients. Advocacy should be based on evidence from research and monitoring programs, and technical concepts should be translated in lay language through communication tools that address all the stakeholders. The fight to ensure universal access to quality medicines needs the participation of all, and can only be successful if grounded in common understanding.en
dc.languageENG-
dc.language.isoenen
dc.publisherBioMed Centralen
dc.rightsArchived with thanks to Journal of Pharmaceutical Policy and Practiceen
dc.titleFighting Poor-Quality Medicines in Low- And Middle-Income Countries: The Importance of Advocacy and Pedagogyen
dc.identifier.journalJournal of Pharmaceutical Policy and Practiceen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.